JointHealth™ express February 6, 2014
Just a few days left to let BC PharmaCare hear “Your Voice” on tocilizumab
You can provide feedback to British Columbia’s Ministry of Health about tocilizumab (Actemra®) for the treatment of polyarticular juvenile idiopathic arthritis
Do you live with or know someone who lives with polyarticular juvenile idiopathic arthritis (pJIA)? Do you care for someone, or does your organization represent people, with pJIA? You can provide feedback to British Columbia’s Ministry of Health about tocilizumab (Actemra®) for the treatment of pJIA, via a website called Your Voice. To view the information sheet for tocilizumab, please click here.
Through this website, patients, caregivers, and patient groups can add their voices to the BC PharmaCare drug review process by filling out an online questionnaire.
The input is reviewed by the Drug Benefit Council, which then gives recommendations on whether a medication should be covered, and how, by BC PharmaCare. BC PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process.
It is an opportunity for you to share your perspectives on medication decisions that affect you.
Please click here to let BC PharmaCare hear Your Voice. Or, you can email us your input at feedback@jointhealth.org or call us at 604-974-1366. We can send it as a patient group on your behalf.
The deadline for submission is February 11, 2014. Please provide your input to us by Monday, February 10 so that we may submit the questionnaire in time for the deadline.
Just a few days left to let BC PharmaCare hear “Your Voice” on tocilizumab
You can provide feedback to British Columbia’s Ministry of Health about tocilizumab (Actemra®) for the treatment of polyarticular juvenile idiopathic arthritis
Do you live with or know someone who lives with polyarticular juvenile idiopathic arthritis (pJIA)? Do you care for someone, or does your organization represent people, with pJIA? You can provide feedback to British Columbia’s Ministry of Health about tocilizumab (Actemra®) for the treatment of pJIA, via a website called Your Voice. To view the information sheet for tocilizumab, please click here.
Through this website, patients, caregivers, and patient groups can add their voices to the BC PharmaCare drug review process by filling out an online questionnaire.
The input is reviewed by the Drug Benefit Council, which then gives recommendations on whether a medication should be covered, and how, by BC PharmaCare. BC PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process.
It is an opportunity for you to share your perspectives on medication decisions that affect you.
Please click here to let BC PharmaCare hear Your Voice. Or, you can email us your input at feedback@jointhealth.org or call us at 604-974-1366. We can send it as a patient group on your behalf.
The deadline for submission is February 11, 2014. Please provide your input to us by Monday, February 10 so that we may submit the questionnaire in time for the deadline.
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.